Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0012116
UniProt IDP07550
Primary gene name(s)ADRB2
Synonym gene name(s)ADRB2R, B2AR
Protein nameBeta-2 adrenergic receptor
Protein functionBeta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. {ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}.
Subcellular locationCell membrane {ECO:0000269|PubMed:19584355, ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:25220262, ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137};
Multi-pass membrane protein {ECO:0000269|PubMed:19584355}. Early endosome {ECO:0000269|PubMed:20559325}. Note=Colocalizes with VHL at the cell membrane, PubMed:19584355. Activated receptors are internalized into endosomes prior to their degradation in lysosomes, PubMed:20559325. {ECO:0000269|PubMed:19584355, ECO:0000269|PubMed:20559325}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P07550
Gene Ontology
(Biological Process)
Complete annatation
activation of adenylate cyclase activity [GO:0007190];
activation of transmembrane receptor protein tyrosine kinase activity [GO:0007171];
adenylate cyclase-activating adrenergic receptor signaling pathway [GO:0071880];
adenylate cyclase-modulating G-protein coupled receptor signaling pathway [GO:0007188];
bone resorption [GO:0045453];
brown fat cell differentiation [GO:0050873];
cell-cell signaling [GO:0007267];
cell surface receptor signaling pathway [GO:0007166];
desensitization of G-protein coupled receptor protein signaling pathway by arrestin [GO:0002032];
diet induced thermogenesis [GO:0002024];
endosome to lysosome transport [GO:0008333];
heat generation [GO:0031649];
negative regulation of multicellular organism growth [GO:0040015];
negative regulation of smooth muscle contraction [GO:0045986];
positive regulation of autophagosome maturation [GO:1901098];
positive regulation of bone mineralization [GO:0030501];
positive regulation of lipophagy [GO:1904504];
positive regulation of MAPK cascade [GO:0043410];
positive regulation of protein ubiquitination [GO:0031398];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
receptor-mediated endocytosis [GO:0006898];
regulation of sodium ion transport [GO:0002028];
regulation of vasodilation [GO:0042312];
response to cold [GO:0009409];
vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure [GO:0002025]
Gene Ontology
(Molecular Function)
Complete annatation
beta2-adrenergic receptor activity [GO:0004941];
dopamine binding [GO:0035240];
drug binding [GO:0008144];
epinephrine binding [GO:0051379];
norepinephrine binding [GO:0051380];
potassium channel regulator activity [GO:0015459];
protein homodimerization activity [GO:0042803]
Gene Ontology
(Cellular Component)
Complete annatation
apical plasma membrane [GO:0016324];
axon [GO:0030424];
caveola [GO:0005901];
dendritic spine [GO:0043197];
early endosome [GO:0005769];
endosome [GO:0005768];
integral component of plasma membrane [GO:0005887];
lysosome [GO:0005764];
neuronal cell body membrane [GO:0032809];
nucleus [GO:0005634];
plasma membrane [GO:0005886];
receptor complex [GO:0043235];
sarcolemma [GO:0042383]
Protein-protein interaction106663
Phylogenetic treeP07550
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-2.947059186660622.21181959236816e-061.58821080972715e-05
AZA vs. DISU-0.4410722611825870.5450510014088370.944487733674769
AZA vs. IL7-0.5894329119714590.4119151466845230.999311006273513
AZA vs. SAHA-0.1083714234007370.8770754030946380.972650433588392
DISU vs. CD32.496551059588170.0001250004279605980.000689446195052341
DISU vs. IL7-0.1615963915104040.8275684092416440.963362100151845
DISU vs. SAHA0.338037256806280.6410433308165110.889153447537328
DMSO vs. AZA-0.07900719859136750.912951586184381
DMSO vs. CD32.874516407421441.60815515906076e-058.82902969068893e-05
DMSO vs. DISU0.3653125040894470.6260385656827690.944952148943607
DMSO vs. IL7-0.5062316077049230.4937856742676750.885378142451182
DMSO vs. SAHA-0.03594880750087720.9603548862518820.99083695162456
HIV vs. Mock in Activationunknownunknownunknown
HIV vs. Mock in Latency1.617577203136311.11022302462516e-161.67355018731996e-13
IL7 vs. CD32.358099979835220.0001496030169897410.000829336621951588
SAHA vs. CD32.822070331903694.12516394565632e-062.8740740018974e-05
SAHA vs. IL70.4845495855966260.4991021575871080.727982909613296
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.521717 0.00847342
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00521 Carteolol approved yes antagonist
DB00816 Orciprenaline approved yes agonist
DB00867 Ritodrine approved yes agonist
DB00871 Terbutaline approved yes agonist
DB00901 Bitolterol withdrawn yes unknown
DB00938 Salmeterol approved yes agonist
DB00983 Formoterol approved, investigational yes agonist
DB01001 Salbutamol approved, vet_approved yes agonist
DB00373 Timolol approved yes antagonist
DB00571 Propranolol approved, investigational unknown antagonist
DB00598 Labetalol approved yes antagonist
DB00612 Bisoprolol approved unknown antagonist
DB00668 Epinephrine approved, vet_approved yes agonist
DB00852 Pseudoephedrine approved unknown partial agonist
DB00866 Alprenolol approved, withdrawn yes antagonist
DB00960 Pindolol approved unknown partial agonist
DB01064 Isoprenaline approved yes agonist
DB01151 Desipramine approved unknown antagonist
DB01203 Nadolol approved unknown antagonist
DB01210 Levobunolol approved yes antagonist
DB01214 Metipranolol approved yes antagonist
DB01274 Arformoterol approved, investigational yes agonist
DB01366 Procaterol approved yes agonist
DB01407 Clenbuterol approved, vet_approved yes agonist
DB01136 Carvedilol approved, investigational unknown antagonist
DB01288 Fenoterol approved yes agonist
DB01291 Pirbuterol approved yes agonist
DB01580 Oxprenolol approved unknown antagonist
DB01359 Penbutolol approved, investigational yes antagonist
DB00368 Norepinephrine approved yes agonist
DB01408 Bambuterol approved yes agonist
DB05039 Indacaterol approved yes agonist
DB05849 NCX 950 investigational unknown unknown
DB06262 Droxidopa approved, investigational yes agonist
DB00264 Metoprolol approved, investigational unknown antagonist
DB00195 Betaxolol approved unknown antagonist
DB00489 Sotalol approved yes antagonist
DB01295 Bevantolol approved unknown antagonist
DB01193 Acebutolol approved unknown partial agonist
DB01102 Arbutamine approved unknown agonist
DB00841 Dobutamine approved unknown agonist
DB07543 (2S)-1-(9H-Carbazol-4-yloxy)-3-(isopropylamino)propan-2-ol experimental unknown unknown
DB00449 Dipivefrin approved yes agonist
DB08807 Bopindolol approved unknown partial agonist
DB08808 Bupranolol approved unknown antagonist
DB04861 Nebivolol approved, investigational unknown antagonist
DB00925 Phenoxybenzamine approved unknown unknown
DB01363 Ephedra approved, nutraceutical, withdrawn yes agonist
DB06216 Asenapine approved unknown antagonist
DB00370 Mirtazapine approved unknown binder
DB00248 Cabergoline approved unknown binder
DB00221 Isoetarine approved unknown agonist
DB00335 Atenolol approved unknown unknown
DB00397 Phenylpropanolamine approved, vet_approved, withdrawn unknown agonist
DB09080 Olodaterol approved yes agonist
DB09082 Vilanterol approved yes agonist
DB04846 Celiprolol approved, investigational yes agonist
DB00182 Amphetamine approved, illicit unknown agonist
DB00540 Nortriptyline approved unknown antagonist
DB00726 Trimipramine approved unknown binder
DB00334 Olanzapine approved, investigational unknown unknown
DB00217 Bethanidine approved unknown antagonist
DB00321 Amitriptyline approved unknown binder
DB01365 Mephentermine approved unknown agonist
DB06726 Bufuralol experimental, investigational unknown antagonist

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1GQ4 X-ray 1.9Å A=409-413.
2R4R X-ray 3.4Å A=1-365.
2R4S X-ray 3.4Å A=24-365.
2RH1 X-ray 2.4Å A=1-230# A=263-365.
3D4S X-ray 2.8Å A=1-230# A=263-348.
3KJ6 X-ray 3.4Å A=2-365.
3NY8 X-ray 2.8Å A=1-230# A=263-348.
3NY9 X-ray 2.8Å A=1-230# A=263-348.
3NYA X-ray 3.1Å A=1-230# A=263-348.
3P0G X-ray 3.5Å A=1-230# A=263-365.
3PDS X-ray 3.5Å A=25-230# A=264-348.
3SN6 X-ray 3.2Å R=29-365.
4GBR X-ray 3.9Å A=29-365.
4LDE X-ray 2.7Å A=29-348.
4LDL X-ray 3.1Å A=29-348.
4LDO X-ray 3.2Å A=29-348.
4QKX X-ray 3.3Å A=29-348.
5D5A X-ray 2.4Å A=1-230# A=263-365.
5D5B X-ray 3.8Å A=1-230# A=263-365.
5D6L X-ray 3.2Å A=1-223# A=264-365.
5JQH X-ray 3.2Å A/B=30-348.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04020 Calcium signaling pathway - Homo sapiens (human)
hsa04022 cGMP-PKG signaling pathway - Homo sapiens (human)
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04080 Neuroactive ligand-receptor interaction - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04261 Adrenergic signaling in cardiomyocytes - Homo sapiens (human)
hsa04923 Regulation of lipolysis in adipocytes - Homo sapiens (human)
hsa04924 Renin secretion - Homo sapiens (human)
hsa04970 Salivary secretion - Homo sapiens (human)